What's new

Covid origins investigation: US House of Representatives holds first hearing

Experts see different symptoms in Beijing outbreak

Medical workers in Beijing are finding that new patients being treated for Covid-19 are experiencing “strange” symptoms, including joint and stomach discomfort.

They are also finding that “different weather, living habits and body types may result in symptoms varying in different regions”, according to the national Global Times newspaper.

This is not the first time Chinese specialists have seen the virus "change". In mid-May, specialists treating the virus in the north-east noticed different symptoms in patients - fatigue or a sore throat, as opposed to a fever or a persistent cough.

There are concerns that the fresh spate of cases in the Chinese capital could lead to a second wave of Covid-19 nationally.

So far, 137 cases have been reported since 11 June. China’s media say the newly confirmed cases are mild and mainly affect younger people.

People’s Daily has given a statistical breakdown of 106 patients confirmed between 11 and 15 June.

Most are aged 30-39, and the fewest patients are recorded in the 60 and above category (five men and six women). Nobody has tested positive under the age of 20.
 
WHO testing interim data from COVID-19 trial on HIV drugs

The World Health Organization is looking at interim data from its large multi-country trial of the combination of HIV drugs Lopinavir and Ritonavir to treat COVID-19 patients, the UN agency's chief scientist Soumya Swaminathan said.

Her comments come after the WHO on Wednesday stopped testing of the malaria drug hydroxychloroquine in the trial of treatments for COVID-19 patients, after studies indicated it showed no benefit in those who have the disease.

She said more study was needed to see whether hydroxchloroquine could prevent infection.
 
Coronavirus was already in Italy by December, waste water study finds

Italian scientists say sewage water from two cities contained coronavirus traces in December, long before the country's first confirmed cases.

The National Institute of Health (ISS) said water from Milan and Turin showed genetic virus traces on 18 December.

It adds to evidence from other countries that the virus may have been circulating much earlier than thought.

Chinese officials confirmed the first cases at the end of December. Italy's first case was in mid-February.

In May French scientists said tests on samples showed a patient treated for suspected pneumonia near Paris on 27 December actually had the coronavirus.

Meanwhile in Spain a study found virus traces in waste water collected in mid-January in Barcelona, some 40 days before the first local case was discovered.

In their study, ISS scientists examined 40 sewage samples collected from wastewater treatment plants in northern Italy between last October and February.

Samples from October and November came back negative, showing that the virus had not yet arrived, ISS water quality expert Giuseppina La Rosa said. Waste water from Bologna began showing traces of the virus in January.

The findings could help scientists understand how the virus began spreading in Italy, Ms La Rosa said.

However she said the research did not "automatically imply that the main transmission chains that led to the development of the epidemic in our country originated from these very first cases".

Italy's first known non-imported virus case was a patient in the town of Codogno in the Lombardy region. The town was closed off and declared a "red zone" on 21 February. Nine other towns in Lombardy and neighbouring Veneto followed and the entire country went into lockdown in early March.

The ISS said the results confirmed the "strategic importance" of sewage water as an early detection tool because it can signal the virus's presence before cases are clinically confirmed. Many countries are now using the technique.

The institute says it aims to begin a pilot project monitoring waste water at tourist resorts in July with a view to setting up a nationwide waste water monitoring network later this year.

More than 40,000 people have died of Covid-19 in Italy.

https://www.bbc.com/news/world-europe-53106444
 
<blockquote class="twitter-tweet"><p lang="en" dir="ltr">Ivermectin Shows Promise Against COVID<br><br>This paper summarizes 50-years of experience with ivermectin against >15 viruses<br><br>In the lab, ivermectin killed coronavirus within 48-hours<br><br>Need robust human trials to see if its safe/works<br><br>Don’t self medicate:)<a href="https://t.co/wYYlApfq7x">https://t.co/wYYlApfq7x</a></p>— Faheem Younus, MD (@FaheemYounus) <a href="https://twitter.com/FaheemYounus/status/1274564128473038848?ref_src=twsrc%5Etfw">June 21, 2020</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
 
'No-swab' saliva test for cornavirus piloted in UK

A weekly coronavirus testing regime using a "no-swab" saliva test is being trialed in Southampton, southern England, and could result in a simpler and quicker way to detect outbreaks of the virus, the UK government said.

"Saliva testing could potentially make it even easier for people to take coronavirus tests at home, without having to use swabs," said Health Secretary Matt Hancock. "This trial will also help us learn if routine, at-home testing could pick up cases of the virus earlier."

More than 14,000 doctors and health workers, other essential workers and university staff and their households will participate in the trial, which uses an Optigene test, the government said.

Rather than taking a swab, which some people find uncomfortable, participants will spit into a pot. Test results will be received within 48 hours, the government said.
 
Some scientists suspect that Covid-19 causes respiratory failure and death not through damage to the lungs, but the brain – and other symptoms include headaches, strokes and seizures.

For Julie Helms, it started with a handful of patients admitted to her intensive care unit at Strasbourg University Hospital in northeast France in early March 2020. Within days, every single patient in the ICU had Covid-19 – and it was not just their breathing difficulties that alarmed her.

“They were extremely agitated, and many had neurological problems – mainly confusion and delirium,” she says. “We are used to having some patients in the ICU who are agitated and require sedation, but this was completely abnormal. It has been very scary, especially because many of the people we treated were very young – many in their 30s and 40s, even an 18-year-old.”

Helms and her colleagues published a small study in the New England Journal of Medicine documenting the neurological symptoms in their Covid-19 patients, ranging from cognitive difficulties to confusion. All are signs of “encephalopathy” (the general term for damage to the brain) – a trend that researchers in Wuhan had noticed in coronavirus patients there in February.

Now, more than 300 studies from around the world have found a prevalence of neurological abnormalities in Covid-19 patients, including mild symptoms like headaches, loss of smell (anosmia) and tingling sensations (arcoparasthesia), up to more severe outcomes such as aphasia (inability to speak), strokes and seizures. This is in addition to recent findings that the virus, which has been largely considered to be a respiratory disease, can also wreak havoc on the kidneys, liver, heart, and just about every organ system in the body.

“We don’t know yet if the encephalopathy is more severe with Covid-19 than with other viruses, but I can tell you we’ve been seeing quite a lot of it,” says neurologist Elissa Fory of the Henry Ford Foundation in Detroit, Michigan. “As the number of cases increases, you will start to see not only the common manifestations but also the uncommon manifestations – and we’re seeing them all at once, which is not something any of us have encountered in our lifetimes.”

Estimates of exact prevalence vary, but it seems that roughly 50% of patients diagnosed with Sars-CoV-2 – the virus responsible for causing the illness Covid-19 – have experienced neurological problems.

The extent and severity of these neurological issues has flown largely under the radar. Most people, including physicians, may not recognise neurological abnormalities for what they are when they appear – someone experiencing a seizure may simply look dazed, without any trembling or shaking. With its beeping machinery, sedative drugs and bed-bound isolation, an ICU environment can exacerbate and induce delirium, confounding our ability to link any symptom to the virus.

Further complicating matters, many people suffering from the effects of Sars-CoV-2 are never actually tested for the virus, especially if they do not exhibit a cough or fever. It means that if they have neurological symptoms, we may never know if this was linked to Sars-CoV-2.

“In fact, there is a significant percentage of Covid-19 patients whose only symptom is confusion” – they don't have a cough or fatigue, says Robert Stevens, associate professor of anaesthesiology and critical care medicine at Johns Hopkins Medicine in Baltimore, Maryland.

“We are facing a secondary pandemic of neurological disease.”

A different disease

Since the start of the pandemic, it has become increasingly clear that Sars-CoV-2 is not just a turbo-charged version of the virus that causes the common cold: it has a number of quirky, unusual and sometimes terrifying traits.

For example, most viral pandemics (including influenza) have a “U shaped” mortality curve, killing the very young and the very old. But Sars-CoV-2 typically only causes mild symptoms in children. The novel coronavirus also disproportionately affects men: up to 70% of people admitted to ICUs worldwide have been male, though men and women have been infected at equal rates. (Read more about how Covid-19 affects men and women differently).

“Happy hypoxia” is another mystery. Our blood normally features “oxygen saturation” levels of around 98%. Anything below 85% should lead to a loss of consciousness, coma or even death. But a large number of Covid-19 patients have been found to have oxygen saturation levels below 70%, even below 60%, yet remained fully conscious and cognitively functional.

Then there’s the fact that an enormous percentage of people who carry the virus have no symptoms. Estimates vary, but one mass-testing report from Iceland found that fully 50% of the population who carried the virus expressed no symptoms whatsoever.

Perhaps most unnerving: while about 80% of people who develop Covid-19 shake off the virus easily, a small percentage quickly worsen and within days die from respiratory weakness and multi-system organ failure. Many of these patients are elderly or have particular underlying health conditions, but not all.

We’ve now learned that the disease affects many different organ systems: patients can die not only from lung failure, but also kidney failure, blood clots, liver abnormalities, and neurological manifestations – Robert Stevens

“If we have learned anything over the past couple of months, it is that this disease, Covid-19, is extremely heterogeneous in presentation,” says Stevens. “We’ve now learned that the disease affects many different organ systems: patients can die not only from lung failure, but also kidney failure, blood clots, liver abnormalities, and neurological manifestations.

“I’ve had patients in the ICU recover in two to three days. I’ve got others who have been in hospital now for months.”

There are other quirks that Stevens has noticed but cannot explain. “Covid-19 patients seem to have a lack of sensitivity to the drugs we normally use – we’ve had to use five to 10 times the amount of drugs for sedation that we would normally use,” he says.

Virologists will spend years trying to understand the biomechanics of this invader. And though researchers have scrutinised the virus and its victims for six months, publishing scientific studies at a rate never before seen with any disease, we still have more questions than answers. The newest to be added is: can the virus infect the brain?

Brain symptoms

Most researchers believe the neurological effect of the virus are an indirect result of either oxygen starvation to the brain (the “happy hypoxia” exhibited by many patients), or the byproduct of the body’s inflammatory response (the famed “cytokine storm”). Both Fory and Helms believe the neurological effects are “cytokine-mediated”.

Others aren’t so certain: evidence is starting to accumulate demonstrating that the virus can actually invade the brain itself.

In Japan, researchers reported the case of a 24-year-old man who was found unconscious on the floor in a pool of his own vomit. He experienced generalised seizures while being rushed to hospital. An MRI scan of his brain revealed acute signs of viral meningitis (inflammation of the brain), and a lumbar puncture detected Sars-CoV-2 in his cerebrospinal fluid. Chinese researchers also found traces of the virus in the cerebrospinal fluid of a 56-year-old male patient suffering from severe encephalitis. And in a post-mortem examination of a Covid-19 patient in Italy, researchers detected viral particles in the endothelial cells lining the blood vessels of the brain itself. In some countries such as France, autopsies of Covid-19 patients are highly restricted (or outright banned), making the Italian finding all the more important – and concerning.

In fact, some scientists now suspect that the virus causes respiratory failure and death not through damage to the lungs but through damage to the brainstem, the command centre that ensures we continue to breathe even when unconscious.

The brain is normally shielded from infectious diseases by what is known as the “blood-brain barrier” – a lining of specialised cells inside the capillaries running through the brain and spinal cord. These block microbes and other toxic agents from infecting the brain.

If Sars-CoV-2 can cross this barrier, it suggests that not only can the virus get into the core of the central nervous system, but also that it may remain there, with the potential to return years down the line.

Though rare, this Lazarus-like behaviour is not unknown among viruses: the chickenpox virus Herpes zoster, for example, commonly infects the nerve cells in the spine, later reappearing in adulthood as shingles – roughly 30% of people who experienced chickenpox in childhood will develop shingles at some point in their lives.

Other viruses have caused far more devastating long term impacts. One of the most notorious was the influenza virus responsible for the 1918 pandemic, which caused permanent and profound damage to the dopamine neurons of the brain and central nervous system. (While it’s long been assumed that influenza cannot cross the blood-brain barrier, some scientists now think that it can). An estimated five million people worldwide were hobbled by a form of extreme exhaustion known as “sleepy sickness” or “encephalitis lethargica”.

Among those who survived, many remained in a state of suspended animation. “They neither conveyed nor felt the feeling of life; they were as insubstantial as ghosts, and as passive as zombies,” wrote Oliver Sacks in his 1973 memoir Awakenings. He described patients remaining in this stupor for decades until being revived by the drug L-DOPA, replenishing levels of the neurotransmitter dopamine. (Read more about why the 1918 flu was so deadly).

David Nutt, professor of neuropsychopharmacology at Imperial College London, says he himself treated many patients in the 1970s and 1980s who had suffered from severe clinical depression ever since the 1957 influenza pandemic in the UK.

“Their depression was enduring and it was solid – it was if their emotional circuits had all been switched off,” he says, warning that we could see the very same thing happen again, but on a much larger scale. “People who are discharged from the ICU with Covid-19 need to be monitored systematically long-term for any evidence of neurological damage – and then given interventionist treatments if necessary.”

Patients who exhibit symptoms should be moved into interventional trials, such as of selective serotonin reuptake inhibitors (SSRI) anti-depressants or beta interferons (naturally-occurring proteins often administered as drugs for conditions such as multiple sclerosis) to mitigate the damage and prevent further long-term effects. But this simply isn’t being done, he says: “What really bugs me is that every health trust in the UK is looking at the symptoms of Covid – but nobody is looking at the neurological mechanisms, such as the amount of serotonin in the brain.”

Nutt plans to enroll 20 Covid-19 patients who developed depression or another neuro-psychiatric condition into a study that will use Imperial’s state-of-the-art PET scanners to look for signs of brain inflammation or abnormalities in neurotransmitter levels.

In Baltimore, Stevens is also planning a long-term study on Covid-19 patients discharged from the ICU, which will also conduct brain scans as well as detailed cognitive tests on functions such as memory capacity.

And in Pittsburgh, through the Global Consortium Study of Neurological Dysfunction in Covid-19, Sherry Chou, a neurologist at the University of Pittsburgh, has coordinated scientists from 17 countries to collectively monitor the neurological symptoms of the pandemic, including through brain scans.

The virus’s impact on the nervous system could be far larger and more devastating than its impact on the lungs
Although the virus’s impact on the lungs is the most immediate and terrifying threat, the lasting impact on the nervous system be far larger and far more devastating, says Chou.

“Even though neurological symptoms are less common in Covid-19 than lung problems, recovery from neurological injuries is often incomplete and can take much longer compared to other organ systems (for example, lung), and therefore result in much greater overall disability, and possibly more death,” she says.

In France, Helms knows better than almost anyone how intense the neurological impacts can be. We needed to delay her interview with the BBC after one of her Covid-19 patients – who was discharged from the hospital two months ago, but is still suffering from viral fatigue and severe depression – required urgent consultation for suicidal risk. And that patient is not unique – she has seen many people in similar states of distress.

“She is confused, she cannot walk, and she just wants to die, it’s really awful,” says Helms. “She’s only 60, but she has said to me ‘Covid has killed me’ – meaning it has killed her brain. She just doesn’t want anything more in life.

“This has been especially difficult because we don’t know how to prevent this damage in the first place. We just don’t have any treatments that will prevent any damage to the brain.”

Patients experiencing lung failure can be put on a respirator, and kidneys can be rescued with a dialysis machine – and, with some luck, both organs will bounce back. But there is no dialysis machine for the brain.

https://www.bbc.com/future/article/20200622-the-long-term-effects-of-covid-19-infection
 
Newborn Mexican triplets test positive for coronavirus in 'unprecedented' case

Newborn triplets in Mexico have tested positive for coronavirus in an "unprecedented" case, according to local health authorities.

Medical experts are investigating whether the disease could have been passed on through the mother's placenta during pregnancy.

Two of the babies, one boy and one girl, are in a stable condition in a hospital in San Luis Potosí state.

But the second boy is receiving treatment for a respiratory condition.

A spokesperson for the state's Health Safety Committee said contagion in multiple births had not been detected anywhere globally and so the case would be investigated.

A very small number of newborn babies have been known to pick up the virus after birth, but health officials say they do not believe this is what happened in this case.

State Health Secretary Mónica Liliana Rangel Martínez said: "It would be impossible for them to have been infected at the moment of birth."

However, the parents are currently being tested, with authorities saying they may have been asymptomatic.

Mexico has recorded more than 185,000 coronavirus cases and 22,584 deaths since the country's first case on 28 February.

Coronavirus in newborns

The triplets - born prematurely on 17 June in Mexico - all tested positive for coronavirus on the day of their birth.

Coronavirus in newborns is unusual, but not unheard of. Babies can catch the virus after birth if they have close contact with anyone who is already infected. Coronavirus might also be passed on in the womb from mother to baby via the placenta.

US researchers from Yale School of Medicine recently reported the first known case of placental infection with coronavirus. When infection does occur, the risk to mother and baby is often low - although some reports suggest it might increase the likelihood of babies being born early.

There is no evidence that the virus causes miscarriage or affects how your baby develops in pregnancy, but, as a precaution, pregnant women are advised to be strict about avoiding close social contact to reduce their chance of getting coronavirus. If they do become infected, most mums-to-be will have mild or moderate symptoms and recover. Babies may show no signs of the illness at all. If you are caring for a baby, you can reduce their risk of getting the virus by keeping your hands clean with regular hand washing.
https://www.bbc.com/news/world-latin-america-53147483
 
Covid-19 antibody tests for NHS and care staff are being rolled out without "adequate assessment", experts warn.

The tests could place an unnecessary burden on the NHS, the 14 senior academics say in a letter in the BMJ,

Last month, the government said it had bought 10 million antibody tests and asked NHS trusts and care homes to make them available to staff in England.

Officials say the blood tests - to see if someone has had the virus - will play an "increasingly important role".

Some patients and people having routine blood tests in England are being offered them too.

What are antibody tests?

They normally show if someone - who has previously been unwell with a bug - has developed antibodies that offer protection against future bouts of the illness.

But how the immune system reacts to the Covid-19 virus remains uncertain.

With the current laboratory tests, NHS England says, a positive result shows a person has had coronavirus.

But crucially, it does not prove they have immunity against future attacks or whether they could transmit the virus to others.

Nevertheless, health officials say gathering the results of these tests will help them understand more about the spread of disease.

What are the concerns?
The group of scientists say as a positive result is unable to prove immunity, the tests offer "no benefit" to hospitals and care staff.

The results do not change what personal protective equipment staff must wear, for example.

The academics also suggest there is little data on how well the test works for people at highest risk - including people belonging to some ethnic minorities and older patients.

Instead, they call for other carefully designed strategies to help monitor the spread of the virus.

What do other experts think?
Prof Sir John Bell from Oxford University, who has advised the government on antibody tests, said the academics who wrote to the BMJ had underestimated the value of the tests.

"We do need to know how many people out there have been infected and the only way to do this is antibody testing," he told BBC Radio 4's Today programme.

But he said they were right to say there was not enough evidence that a positive test indicated immunity. "You couldn't safely use it as a way of telling people whether they could be exposed or not," he said.

Prof Martin Hibberd, of the London School of Hygiene and Tropical Medicine, described the tests as an important component of the public-health response.

He added: "If used successfully, the data generated will be important surveillance information for understanding the effectiveness of control measures put in place."

Meanwhile Dr Tom Wingfield, at the Liverpool School of Tropical Medicine, said he shared the concerns raised in the academics' letter.

He added: "We don't yet have sufficient evidence on accuracy and interpretation of antibody tests."

A Public Health England official said all tests in the programme had been "extensively validated by the manufacturers and have received CE marks" indicating compliance with EU safety standards.

Public Health England has launched a study - using antibodies and other tests - to see if healthcare workers develop immunity.

What about other parts of the UK?
Wales is currently working on its testing policies.

Meanwhile, Scotland's chief medical officer has written to all health boards to say they should not offer "on-demand" antibody testing to NHS staff, care workers or patients.

https://www.bbc.com/news/health-53169618
 
Antibodies found in over 40% of Austrian ski resort's residents

More than 40% of residents in Ischgl, an Austrian ski resort village that was once at the heart of Europe’s coronavirus outbreak, have developed antibodies against Covid-19, a study has found.

Thousands of people, many of them European tourists, were infected there in early March.

Researchers from the Medical University of Innsbruck conducted antibody tests on 1,473 people, about 79% of Ischgl's population.

The study found that 42.4% of those tested had antibodies for Covid-19.

Antibodies are tiny proteins that our immune systems produce in response to bacteria and viruses.

The director of the university's Institute of Virology, Dorothee von Laer, said Ischgl had the highest prevalence of antibodies “ever proven in a study”.

“Even though at that rate herd immunity cannot be assumed, Ischgl's population should be protected [from the virus] to a large extent," she said.

Austria has recorded more than 17,000 infections and almost 700 deaths to date, both relatively low numbers compared to its European neighbours.
 
Coronavirus immunity may be more widespread than tests suggest

People testing negative for coronavirus antibodies may still have some immunity, a study has suggested.

For every person testing positive for antibodies, two were found to have specific T-cells which identify and destroy infected cells.

This was seen even in people who had mild or symptomless cases of Covid-19.

But it's not yet clear whether this just protects that individual, or if it might also stop them from passing on the infection to others.

Researchers at the Karolinksa Institute in Sweden tested 200 people for both antibodies and T-cells.

Some were blood donors while others were tracked down from the group of people first infected in Sweden, mainly returning from earlier affected areas like northern Italy.

This could mean a wider group have some level of immunity to Covid-19 than antibody testing figures, like those published as part of the UK Office for National Statistics Infection Survey, suggest.

It's likely those people did mount an antibody response, but either it had faded or was not detectable by the current tests.

And these people should be protected if they are exposed to the virus for a second time.

Prof Danny Altmann at Imperial College London described the study as "robust, impressive and thorough" and said it added to a growing body of evidence that "antibody testing alone underestimates immunity".

Herd immunity

This doesn't necessarily get us any closer to herd immunity, though, according to assistant professor Marcus Buggert, one of the study's authors.

More analysis needs to be done to understand whether these T-cells provide "sterilising immunity", meaning they completely block the virus, or whether they might protect an individual from getting sick but not stop them from carrying the virus and transmitting it.

Much of the discussion around Covid-19 immunity has focused on antibodies - Y-shaped proteins which act like "missiles shooting down a target", assistant Prof Buggert explained.

They bind to the virus before it can enter your cells, and neutralise it.

If antibodies fail to neutralise the virus, it can enter your cells and turn them into virus-making factories.

T-cells, on the other hand, target already-infected cells and completely destroy them, stopping them from spreading to other, healthy cells.

Like antibodies, T-cells are part of the bit of your immune system that has a memory. Once it recognises a particular virus, it can quickly target cells infected with it and kill them.

A drug called interleukin 7, known to boost T-cell production, is being trialled in the UK to see if it can aid patients' recovery.

T-cell crash

Researchers from the Francis Crick Institute, King's College London and Guys and St Thomas' Hospital noticed a group of 60 severely ill patients appeared to experience a crash in their numbers of T-cells.

This was not observed in the Karolinska study, which found the sicker the patient, the higher the level of antibodies and T-cells they appeared to produce.

The team said more research was needed.

While theirs is the biggest T-cell study done so far, it still involved a relatively small group of patients.

T-cells are very complex and much harder to identify than antibodies, requiring specialist labs and small batches of samples being tested by hand over the course of days.

This means mass testing for T-cells is not a very likely prospect at the moment.
https://www.bbc.com/news/health-53248660
 
More than 200 scientists called for the World Health Organization to acknowledge the coronavirus can spread in the air - a change that could alter some measures taken to stop the pandemic.

In a letter published in the journal Clinical Infectious Diseases, two scientists from Australia and the US wrote that studies have shown "beyond any reasonable doubt that viruses are released during exhalation, talking and coughing in microdroplets small enough to remain aloft in the air".

That means people in certain indoor conditions could be at greater risk of being infected than was previously thought.

The WHO has long maintained that COVID-19 is spread via larger respiratory droplets, most often when people cough or sneeze, that fall to the ground. It has dismissed the possibility of airborne transmission, except for certain high-risk medical procedures, such as when patients are first put on breathing machines.

In a statement on Monday, the UN health agency said it was aware of the article and was reviewing it with technical experts.

'Lack of recognition'

WHO has been criticised in recent weeks and months for its seeming divergence from the scientific community. The organisation for months declined to recommend mask-wearing, partly out of supply concerns and also continued to describe the transmission of COVID-19 from people without symptoms as "rare".

The letter was endorsed by 239 scientists in 32 countries from a variety of fields. It stated the issue of whether or not COVID-19 was airborne was of "heightened significance" as many countries stop restrictive lockdown measures.

The authors cited previous studies suggesting germs closely related to COVID-19 were spread via airborne transmission, and "there is every reason to expect" coronavirus behaves similarly.

They also cited a Washington state choir practise and unpublished research about a poorly ventilated restaurant in Guangzhou, China - each of which raised the possibility of infections from airborne droplets.

"We are concerned that the lack of recognition of the risk of airborne transmission of COVID-19 and the lack of clear recommendations on the control measures against the airborne virus will have significant consequences," the scientists wrote. "People may think they are fully protected by adhering to the current recommendations, but in fact additional airborne interventions are needed."

Scientists around the world have been working furiously to understand the new virus. The US Centers for Disease Control and Prevention said it is thought to mainly jump from person to person through close contact, but added, "We are still learning about how the virus spreads."

Martin McKee, a professor of European public health at the London School of Hygiene and Tropical Medicine who was not linked to the letter, said the scientists' arguments sounded "entirely reasonable".

"Part of the problem is that everybody at WHO was moving with the paradigm of influenza, even though we know there are lots of differences between influenza and coronaviruses," he said.

McKee noted with the UK's recent reopening of its pubs, restaurants and salons, the possibility of airborne coronavirus transmission might mean stricter interventions are needed indoors, including more mask-wearing and continued physical distancing.

"We're getting accumulating evidence about super-spreading events happening in indoor spaces where there are large numbers of people in confined spaces," he said. "Many of these are in exactly the circumstances that governments now want to open up."

The extent to which the coronavirus can be spread by the so-called "airborne" or aerosol route - as opposed to by larger droplets in coughs and sneezes - remains disputed.

Any change in the WHO's assessment of the risk of transmission could affect its current advice on keeping one-metre (three-feet) physical distancing.

Governments, which also rely on the agency for guidance policy, may also have to adjust public health measures aimed at curbing the spread of the virus.

"Especially in the last couple of months, we have been stating several times that we consider airborne transmission as possible but certainly not supported by solid or even clear evidence," Benedetta Allegranzi, the WHO's technical lead for infection prevention and control, was quoted as saying by The New York Times, which first reported the letter's existence.

https://www.aljazeera.com/news/2020...borne-coronavirus-spread-200706172729735.html
 
A new study of people who have caught and recovered from coronavirus raises the prospect that immunity to the virus may be short-lived.

Scientists at King’s College London studied how the body naturally fights off the virus by making antibodies, and how long these last in the weeks and months after recovery.

Almost all of the 96 people in the study had detectable antibodies that could neutralise and stop coronavirus. But levels began to wane over the three months of the study.

What’s not clear yet is whether this decline leaves us vulnerable to the same virus again. Similar short-lived responses are seen with other viruses, like the common cold. So it’s possible that we may be able to get reinfected.

But even if we’re left with no detectable antibodies, that doesn’t necessarily mean we have no immunity. Antibodies are not the only thing that gives us protection. Our bodies can also make T cells to help fight off invaders.

More and longer studies are needed to see what happens if people come into contact with the virus a second or third time. Do they get sick or are they primed to fight it off because their body has already done so before? These types of study will be important for understanding how well a vaccine might work and how often a booster dose might be needed to provide lasting immunity.
 
COVID-19 antibody test passes first major trials in UK with 98.6% accuracy

British ministers are making plans to distribute millions of free coronavirus antibody tests after a version backed by the UK government passed its first major trials, the Daily Telegraph newspaper reported late on Friday.

The fingerprick tests, which can tell within 20 minutes if a person has ever been exposed to the coronavirus, were found to be 98.6 percent accurate in secret human trials held in June, the newspaper reported.

It added the test was developed by Oxford University in partnership with leading UK diagnostics firms.
 
The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it.

The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection.

The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.

The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation - by 79%.

Patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness, Synairgen claims.

It said the trial also indicated "very significant" reductions in breathlessness among patients who received the treatment.

In addition, the average time patients spent in hospital is said to have been reduced by a third, for those receiving the new drug - down from an average of nine days to six days.

The double-blind trial involved 101 volunteers who had been admitted for treatment at nine UK hospitals for Covid-19 infections.

Half of the participants were given the drug, the other half got what is known as a placebo - an inactive substance.

Unconfirmed results

Stock market rules mean Synairgen is obliged to report the preliminary results of the trial.

The results have not been published in a peer-reviewed journal, nor has the full data been made available; so the BBC cannot confirm the claims made for the treatment.

But if the results are as the company says, it will be a very important step forward in the treatment of coronavirus infections.

The scientist in charge of the trial, Tom Wilkinson, says if the results are confirmed in larger studies the new treatment will be "a game changer".

The trial was relatively small but the signal that the treatment benefits patients was unusually strong, he says.

"We couldn't have expected much better results than these," Synairgen chief executive Richard Marsden told the BBC.

He described the results as "a major breakthrough in the treatment of hospitalised Covid-19 patients".

Mr Marsden said the company will be presenting its findings to medical regulators around the world in the next couple of days to see what further information they require in order to approve the treatment.

That process could take months, although the British government, like many others, has said it will work as fast as possible to get promising coronavirus treatments approved.

It is possible it could be given emergency approval, as the anti-viral drug remdesivir was in May.

Another possibility is that permission will be given for more patients to receive the treatment with the effects being carefully monitored to confirm it is safe and effective.

If it does get approval, the drug and the nebulisers used to deliver it would then need to be manufactured in large quantities.

Mr Marsden says he instructed companies to start producing supplies back in April to ensure they would be available should the results be positive.

He says he expects Synairgen to be able to deliver "a few 100,000" doses a month by the winter.

How does the treatment work?
Interferon beta is part of the body's first line of defence against viruses, warning it to expect a viral attack.

The coronavirus seems to suppress its production as part of its strategy to evade our immune systems.

The new drug is a special formulation of interferon beta delivered directly to the airways via a nebuliser which makes the protein into an aerosol.

The idea is that a direct dose of the protein in the lungs will trigger a stronger anti-viral response, even in patients whose immune systems are already weak.

Interferon beta is commonly used in the treatment of multiple sclerosis.

Previous clinical trials conducted by Synairgen have shown that it can stimulate an immune response and that patients with asthma and other chronic lung conditions can comfortably tolerate the treatment.

How was the treatment tested?
No-one involved in the trial knew which patients have been given which treatment until it was over.

"If you know it's a drug, your mind might have a bias," explained Sandy Aitken, one of the nurses who administered the new drug to patients at Southampton Hospital.

Synairgen's drug trial was the template for the Accord programme, a fast-track clinical trial scheme set up by the UK government in April to accelerate the development of new drugs for patients with Covid-19.

The Synairgen team believes the drug could be even more effective at the early stages of infection.

A trial exploring the effects of giving patients who are in high-risk groups the new drug as soon as they are confirmed as having Covid-19 has struggled to find volunteers because there are so few new infections at the moment.

https://www.bbc.co.uk/news/health-53467022
 
Scientists report airborne coronavirus is probably infectious

WASHINGTON: Scien*tists have known for several months the new coronavirus can become suspended in microdroplets expelled by patients when they speak and breathe, but until now there was no proof that these tiny particles are infectious.

A new study by scientists at the University of Nebraska that was uploaded to a medical preprint site this week has shown for the first time that SARS-CoV-2 taken from microdroplets, defined as under five microns, can replicate in lab conditions.

This boosts the hypothesis that normal speaking and breathing, not just coughing and sneezing, are responsible for spreading Covid-19 — and that infectious doses of the virus can travel distances far greater than the six feet (two metres) urged by social distancing guidelines.

The results are still considered preliminary and have not yet appeared in a peer-reviewed journal, which would lend more credibility to the methods devised by the scientists.

The paper was posted to the medrxiv.org website, where most cutting-edge research during the pandemic has first been made public.

The same team wrote a paper in March showing that the virus remains airborne in the rooms of hospitalized Covid-19 patients, and this study will soon be published in a journal, according to the lead author.

“It is actually fairly difficult” to collect the samples, Joshua Santarpia, an associate professor at the University of Nebraska Medical Centre said.

The team used a device the size of a cell phone for the purpose, but “the concentrations are typically very low, your chances of recovering material are small.” The scientists took air samples from five rooms of bedridden patients, at a height of about a foot (30 centimetres) over the foot of their beds.

The patients were talking, which produces microdroplets that become suspended in the air for several hours in what is referred to as an “aerosol,” and some were coughing.

The team managed to collect microdroplets as small as one micron in diameter.

They then placed these samples into a culture to make them grow, finding that three of the 18 samples tested were able to replicate.

For Santarpia, this represents proof that microdroplets, which also travel much greater distances than big droplets, are capable of infecting people. “It is replicated in cell culture and therefore infectious,” he said.

The potential for microdroplet transmission of the coronavirus was at one stage thought to be improbable by health authorities across the world.

Later, scientists began to change their mind and acknowledge it may be a possibility, which is the rationale for universal masking.

The World Health Organisation was among the last to shift its position, doing so on July 7.

“I feel like the debate has become more political than scientific,” said Santarpia.

“I think most scientists that work on infectious diseases agree that there’s likely an airborne component, though we may quibble over how large.” Linsey Marr, a professor at Virginia Tech who is a leading expert on aerial transmission of viruses and wasn’t involved in the study, said it was rare to obtain measurements of the amount of virus present in air.

“Based on what we know about other diseases and what we know so far about SARS-CoV-2, I think we can assume that if the virus is ‘infectious in aerosols,’ then we can become infected by breathing them in,” she said.

https://www.dawn.com/news/1570629/scientists-report-airborne-coronavirus-is-probably-infectious
 
Sniffer dogs able to detect coronavirus, study finds

Researchers in Germany say they have succesfully managed to train sniffer dogs to detect Sars-Cov-2, the virus that causes Covid-19.

A study by the University of Veterinary Medicine in Hannover, in co-operation with the German army, found that after a week of training, eight dogs were able to correctly differentiate infected samples from control samples in 94% of cases.

The researchers say the findings could be used to help identify the spread of the infection at public areas such as airports and sports events.

Other countries have also begun investigating the potential of sniffer dogs to detect the virus, including the UK.
 
Coronavirus: Obesity increases risks from Covid-19, experts say

Being obese or overweight puts you at greater risk of serious illness or death from Covid-19, experts say after examining existing studies.

The review of evidence by Public Health England found excess weight put people at greater risk of needing hospital admission or intensive care.

And the risk grew substantially as weight increased.

The release comes ahead of an expected government announcement of new measures to curb obesity.

Dr Alison Tedstone, chief nutritionist at Public Health England, said the current evidence was clear, that being overweight or obese puts you at greater risk of serious illness or death from Covid-19, as well as from many other life-threatening diseases.

"Losing weight can bring huge benefits for health - and may also help protect against the health risks of Covid-19," she said. "The case for action on obesity has never been stronger."

The UK has one of the highest levels of obesity in Europe. Almost two-thirds of adults in England are overweight or obese, with similar figures in Wales, Scotland and Northern Ireland.

Am I overweight?

The NHS says most adults with a body mass index (BMI) of 25 to 29.9 are overweight, while those with a BMI of 30 to 39.9 are classed as obese.

Body mass index is calculated by dividing a person's mass in kilograms by the square of their height in metres.

Another measure of excess fat is waist size - men with a waist of 94cm or more and women with a waist of 80cm or more are more likely to develop obesity-related problems.

Supporting people to achieve and maintain a healthy weight may reduce the severe effects of Covid-19 on the population, especially among vulnerable groups who are most affected by obesity, the report said.

Prof Susan Jebb of the University of Oxford, said we already know that older people, men, those from South Asian and some other ethnic groups, and people living in more deprived areas, are at increased risk from Covid-19.

"Over and above these things, this review shows that excess weight is another very important risk factor," she said.

There was anecdotal evidence that some people were struggling with their weight during the pandemic, she added, which offered a "re-set moment" for everyone to think about their lifestyle.

According to the report, while some data suggests that more people have exercised during lockdown, evidence indicates that the nation's exercise levels have not increased overall.

Meanwhile, snack food and alcohol sales from High Street shops have increased.

Boris Johnson is expected to announce new measures soon to combat obesity, including a ban on TV junk food adverts before 21:00.

The measures are yet to be finalised, but are also likely to include a ban on online ads for unhealthy foods, and limits on in-store promotions.

https://www.bbc.co.uk/news/health-53532228
 
Water can kill new coronavirus, Russian scientists find

A study by Russian scientists has shown that water can almost completely destroy the novel coronavirus within 72 hours.

The virus’ resilience is directly dependent on the water temperature – 90% of virus particles die in room temperature water in 24 hours and 99.9% within 72 hours, according to a study by the State Research Centre of Virology and Biotechnology VECTOR.

Water at boiling temperature kills the Sars-CoV-2 virus completely and instantly, says the research published on Thursday by the Russian Federal Service for Human Wellbeing.

The virus can live in water in certain conditions, but it does not multiply in either sea or fresh water, the study showed.

It also remains active up to 48 hours on stainless steel, linoleum, glass, plastic, and ceramic surfaces.

The research found that the virus is unstable and most household disinfectants are effective against it.

It showed that ethyl and isopropyl alcohols of 30% concentration can kill up to a million particles of the virus in half a minute, contradicting previous studies that said a concentration of over 60% was necessary.

Disinfectants with chlorine have the same effectiveness, completely clearing a surface of Sars-CoV-2 within 30 seconds, according to the study.

https://tribune.com.pk/story/2257436/water-can-kill-new-coronavirus-russian-scientists-find
 
New 90-minute tests that can detect coronavirus and flu will be rolled out in care homes and laboratories from next week.

The "on-the-spot" swab and DNA tests will help distinguish between Covid-19 and other seasonal illnesses, the government said.

The health secretary said this would be "hugely beneficial" over the winter.

Currently, three quarters of test results are returned within 24 hours and a quarter can take up to two days.

The announcement comes as the government pushed back a July target to regularly test care home staff and residents, saying the number of testing kits had become more limited.

Almost half a million of the new rapid swab tests will be available from next week in adult care settings and labs, with millions more due to be rolled out later in the year.

Additionally, thousands of DNA test machines, which have already been used in eight London hospitals and can analyse nose swabs, will be rolled out across NHS hospitals from September.

Around 5,000 machines will provide 5.8 million tests in the coming months, the department said.

Health Secretary Matt Hancock described these latest innovations in coronavirus testing as "life-saving".

He added: "Millions of new rapid coronavirus tests will provide on-the-spot results in under 90 minutes, helping us to break chains of transmission quickly.

"The fact these tests can detect flu as well as Covid-19 will be hugely beneficial as we head into winter, so patients can follow the right advice to protect themselves and others."

https://www.bbc.com/news/uk-53632043
 
UAE, Israeli firms sign agreement on coronavirus R&D

The Emirati APEX National Investment company has signed a "strategic commercial agreement" with Israel's Tera Group to cooperate on research and development related to COVID-19, including a testing device, UAE state news agency WAM reported.

The deal "is considered the first business to inaugurate trade, economy and effective partnerships between the Emirati and Israeli business sectors, for the benefit of serving humanity by strengthening research and studies on the novel Coronavirus", WAM quoted APEX's chairman Khalifa Yousef Khoury as saying.

The agreement was signed in Abu Dhabi on Saturday, just two days after Israel and the UAE announced an agreement that will lead to full normalisation of diplomatic relations between the two.

It also came after a phone call between US President Donald Trump, Israeli Prime Minister Benjamin Netanyahu and Sheikh Mohammed bin Zayed Al Nahyan, crown prince of Abu Dhabi.

"The United Arab Emirates and Israel will immediately expand and accelerate cooperation regarding the treatment of and the development of a vaccine for the coronavirus," the two countries said in a joint statement.

Delegations from Israel and the UAE will meet in the coming weeks to sign agreements regarding investment, tourism, direct flights, security, telecommunications and other issues, the joint statement said.

"TeraGroup's BioSafety testing is conducted in selected countries around the world, including the Emirates Field Hospital in Abu Dhabi, with plans to expand the testing to cover the entire UAE," WAM said.

In June, the UAE said two of its private companies and two Israeli companies would work together on medical projects, including to combat the new coronavirus.

Two state-owned Israeli defence contractors in July announced partnerships with Abu Dhabi-based technology company Group 42 to develop technologies to help fight the new coronavirus.

https://www.aljazeera.com/news/2020...gn-agreement-coronavirus-200816071821555.html
 
Malaysia reports mutation of COVID-19 virus

Malaysia's Institute of Medical Research (IMR) has detected a mutation of Covid-19 virus in the country, according to the country's top health official.

Health director-general Datuk Dr Noor Hisham Abdullah said in a social media post that the mutation would likely make existing vaccine ineffective against the disease.

"It was found to be 10 times likely to infect other individuals and easier to spread by super spreader individuals," he wrote, adding

Among those detected to have the mutated coronavirus was an individual from the Philippines.
 
Study links COVID-19 to rise in childhood type 1 diabetes

Cases of type 1 diabetes among children in a small UK study almost doubled during the peak of Britain's COVID-19 epidemic, suggesting a possible link between the two diseases that needs more investigation, scientists said on Tuesday.

While the study is based on only a handful of cases, it is the first to link COVID-19 and new-onset type 1 diabetes in children, and doctors should be on the look-out, the Imperial College London researchers said.

"Our analysis shows that during the peak of the pandemic the number of new cases of type 1 diabetes in children was unusually high in two of the hospitals (we studied) compared to previous years," said Karen Logan, who co-led the study.

"When we investigated further, some of these children had active coronavirus or had previously been exposed to the virus," Logan said.

Logan said previous reports from China and Italy had noted that children were being diagnosed in hospitals with new-onset type 1 diabetes during the pandemic.
 
Hong Kong man re-infected by Covid-19 after four-and-a-half months leading to immunity concerns

A Hong Kong man who recovered from Covid-19 was infected again four-and-a-half months later in the first documented instance of human re-infection, researchers at the University of Hong Kong said on Monday.

The findings indicate the disease, which has killed more than 800,000 people worldwide, will continue to spread amongst the global population despite herd immunity, they said.

The 33-year-old male was cleared of Covid-19 and discharged from a hospital in April, but tested positive again after returning from Spain via Britain on 15 August.

The patient had appeared to be previously healthy, researchers said in the paper, which was accepted by the international medical journal Clinical Infectious Diseases.

He was found to have contracted a different coronavirus strain from the one he had previously contracted and remained asymptomatic for the second infection.

“The finding does not mean taking vaccines will be useless,” Dr Kai-Wang To, one of the leading authors of the paper, told Reuters. “Immunity induced by vaccination can be different from those induced by natural infection,” To said. “[We] will need to wait for the results of the vaccine trials to see if how effective vaccines are.”

The World Health Organization (WHO) epidemiologist Maria Van Kerkhove said on Monday there was no need to jump to any conclusions in response to the Hong Kong case.

Instances of people discharged from hospitals and testing positive again for Covid-19 infection have been reported in mainland China.

However, in those cases it was not clear whether they had contracted the virus again after full recovery – as happened to the Hong Kong patient – or still had the virus in their body from the initial infection.

The preliminary number of patients in China who tested positive again once being discharged from hospital was 5-15%, Wang Guiqiang, an infectious disease specialist in China’s expert group for Covid-19 treatment, said during a press briefing in May.

One explanation was that the virus still existed in the lungs of patients but was not detected in samples taken from upper parts of the respiratory tract, he said. Other possible causes were low sensitivity of tests and weak immunity that could lead to persistent positive results, he added.
 
Obesity 'increases risks from Covid-19'

Being obese doubles the risk of hospital treatment from Covid-19 and increases the risk of dying by nearly 50%, a global analysis suggests.

Obesity makes other diseases such as diabetes and high blood pressure more likely, the US researchers say.

Along with a weakened immune system, this can make these individuals more vulnerable to severe Covid-19.

They also warn a vaccine against coronavirus could be less effective in obese people.

This is based on the fact that flu vaccines don't work as well in those with a body mass index (BMI) of over 30.

The team, from the University of North Carolina, looked at data from 75 studies from around the world for their research, including nearly 400,000 patients.

They found that people with obesity and Covid-19 were twice as likely to end up in hospital and 74% more likely to be admitted to intensive care. They were also more at risk of dying from the disease caused by coronavirus.

Studies from the UK have shown similar risks for people carrying excess weight, prompting the government to introduce new measures to curb obesity.

Professor Barry Popkin, who led the study from the department of nutrition at the University of North Carolina, said the increased risks of being obese and having Covid-19 were "much higher than expected".

He said healthier eating had to be a priority in many countries, with fewer sugary drinks and much less junk and processed food in people's diets.

Obesity is linked to a number of diseases which also put people at higher risk of being ill with Covid-19.

It can also lead to more inflammation in the body, reduce the body's ability to fight off infections and put more strain on other organs, as well as the breathing.

"Vaccine researchers should look at how it affects obese individuals," Prof Popkin says of a coronavirus vaccine to protect against Covid-19.

He is concerned that a vaccine, when it is ready to be used, may be less effective in a population with a high percentage of people with obesity.

With obesity rising around the world and 20% of people overweight or obese in nearly all countries - in the UK and US it's close to 66% - understanding how treatments and vaccines work in this group is "critical", the research says.

https://www.bbc.com/news/health-53921141
 
Researchers identify first case of reinfection in US

Researchers in Nevada reported what may be the first documented case of coronavirus reinfection in the United States, following similar reports earlier this week from Hong Kong and Europe.

A 25-year-old Reno man with mild COVID-19 symptoms initially was found to have the virus in April, recovered and tested negative twice, and then tested positive again in June. He was much sicker the second time, with pneumonia that required hospitalisation and oxygen treatment.

The findings have not yet been published or reviewed by other scientists, but were posted on a research site.
 
Researchers identify first case of reinfection in US

Researchers in Nevada reported what may be the first documented case of coronavirus reinfection in the United States, following similar reports earlier this week from Hong Kong and Europe.

A 25-year-old Reno man with mild COVID-19 symptoms initially was found to have the virus in April, recovered and tested negative twice, and then tested positive again in June. He was much sicker the second time, with pneumonia that required hospitalisation and oxygen treatment.

The findings have not yet been published or reviewed by other scientists, but were posted on a research site.

Not a good news.

Reinfection can be catastrophic.
 
How a $13 device is helping Delhi fight the coronavirus

Twice a day, New Delhi health worker Kamal Kumari receives a flurry of WhatsApp messages from coronavirus patients, containing either a two-digit reading from a tiny medical device or a photo of its glowing display.

She scans the numbers from the 1,000-rupee ($13) oxygen monitor, known as a pulse oximeter, checking to ensure they are all above the prescribed 95 mark and then notes them down in her logbook.

"When we didn't have this, we wouldn't know about their oxygen levels," said Kumari, explaining how her team would worry about patients' conditions rapidly worsening when India's capital was badly short of hospital beds. "Now we can find out in time and safely refer patients to the hospital."

The government of Delhi - where national capital New Delhi is located - has so far distributed pulse oximeters to more than 32,000 people free of charge, putting them at the heart of a plan to isolate most asymptomatic or mildly symptomatic coronavirus patients in their homes.

The programme was devised in May, when coronavirus cases started surging in the densely populated city of 20 million, sending panicked residents rushing to hospitals.

"If we hadn't done this, there would've been no room to even stand in our hospitals," Delhi's health minister, Satyendar Jain, told Reuters.

With more than 3.5 million infections, India has reported the world's third-highest number of coronavirus cases, and states across the country have deployed a variety of measures to fight the pandemic.

In Delhi, health authorities started noticing "happy hypoxemia" - low blood oxygen levels without any breathlessness - that was leading to complications in coronavirus patients isolated at home, Jain said.

For regular monitoring, doctors told Jain that patients would either have to visit hospitals or use the inexpensive oxygen monitors, many of which are made in China.

Delhi has recorded around 173,000 infections with just over 4,400 deaths. Only 14,700 cases remain active and many hospital beds are now empty.

Proactive monitoring
Other cities across the world have also deployed the device.

In May, at the height of its outbreak, Singapore distributed several thousand oximeters to migrant workers isolated in cramped dormitories, which had become an epicentre for the virus's spread.

Singapore's health ministry said oximeters allowed workers "to proactively monitor their own health status and reach out for medical assistance if needed".

In India, too, other states have picked up on Delhi's model. Since late July, the northeastern state of Assam has provided nearly 4,000 oximeters to patients in home isolation.

Some doctors are concerned that patients may not always know how to use the device.

"It's very important to train patients properly on how to use pulse oximeters," said Dr Hemant Kalra, a pulmonologist in New Delhi, adding that cheap, sub-standard oximeters flooding the market were also a problem.

Jain, however, said the government's programme had worked effectively, with not a single fatality among the thousands of patients in home isolation over the last month and a half.

Oximeters have also helped cut down on expensive hospitalisation for mild cases, Jain said, saving more than 10 times the device's price for each day in hospital.

On a warm, humid day last week, Kumari pulled on a protective suit, a mask and goggles, before walking down the narrow lanes of the Chirag Delhi neighbourhood.

Together with a similarly dressed colleague, she stopped at Satish Kumar Soni's home to check on him and three family members who were ending their 10-day isolation period, and to collect two government-issued pulse oximeters.

Soni, a 59-year-old jeweller, said the device helped ease the family's fears and anxiety as they slowly recovered.

"It's not that big a disease," he said. "If the oxygen level is fine, then there isn't much danger."

https://www.aljazeera.com/news/2020...-delhi-fight-coronavirus-200831100141489.html
 
Coronavirus: Cheap hydrocortisone drug reduces deaths in sickest COVID-19 patients, research finds

A cheap and widely available steroid has been found to reduce mortality in the sickest COVID-19 patients.

Hydrocortisone, an anti-inflammatory drug, could save one in every 12 patients and will be recommended for use in NHS coronavirus patients.

It is the second drug found to be effective in reducing mortality in those with severe symptoms of COVID-19.

Researchers from Imperial College London and the Intensive Care National Audit & Research Centre found that patients receiving intensive care who were treated with hydrocortisone for seven days had a 93% chance of a better recovery compared to patients who were not treated with the steroid.

The benefits of hydrocortisone were announced alongside analysis from seven trials involving three different types of steroids - including dexamethasone, which has already been found to reduce mortality and is widely used.

The studies found that treatment with one of dexamethasone, hydrocortisone or methylprednisolone led to an estimated 20% reduction in the risk of death.

Professor Anthony Gordon, who led the research into hydrocortisone, said: "The studies published today show that we now have more than one choice of treatment for those who need it most.

"Steroids are not a cure, but they help improve outcomes. Having a choice of different types of steroids, all of which seem to improve patient recovery, is great as it helps ease the problem of drug supply issues."

A total of 403 patients of various ethnicities were recruited from across the world for the hydrocortisone study, including patients from 88 hospitals in the UK.

Researchers say there is no benefit for choosing to treat a patient with either dexamethasone or hydrocortisone over the other, but it offers more options for cheap and effective and treatments and gives clinicians more choice on what to use.

There were too few patients involved in tests of methylprednisolone to enable researchers to estimate its impact with assurance.

The steroids do not work for those with milder symptoms, but the evidence strongly suggests that they reduce the lung inflammation in patients with COVID-19 who are seriously ill and require oxygen support for their breathing difficulties, regardless of age or sex.

NHS chief executive Sir Simon Stevens said: "One of the distinctive benefits of having our NHS is that we've been able to mobilise quickly and at scale to help researchers test and develop proven coronavirus treatments.

"Just as we did with dexamethasone, the NHS will now take immediate action to ensure that patients who could benefit from treatment with hydrocortisone do so, adding a further weapon in the armoury in the worldwide fight against COVID-19."

Professor Martin Landray, one of the chief investigators of the Oxford University-based RECOVERY trial, which looked at dexamethasone, said: "The results are clear: Among critically ill patients with COVID-19, low-dose corticosteroids such as dexamethasone significantly reduce the risk of death.

"Since the emergence of COVID-19, the search has been on for treatments that can improve survival. Corticosteroids are inexpensive and widely available.

"This additional evidence of their efficacy is therefore particularly welcome as the treatments can be used to save lives worldwide."

https://news.sky.com/story/coronavi...est-covid-19-patients-research-finds-12061777
 
Local startup is using AI to detect Covid-19

Local startup DetectNow is using AI to detect Covid-19. The startup, registered with National Incubation Center(NIC), uses AI to detect the presence of coronavirus by analyzing cough audios.

The startup wanted to offer cost-free screening without delays for coronavirus. Cough is one of the main symptoms of COVID-19 and based on the idea of cough analysis via AI, DetectNow aims to find the unique biosignals of the Covid-19 cough and calculate the probability of a SARS-CoV-2 infection.

The service is available through a web application, making it easy, convenient, and accessible even in low-resource areas, however, the diagnostics function is not live yet, as this will require a medical trial first.

The application has collected 600 samples so far.

DetectNow want to act as an additional tool in fighting Covid-19 by assisting national health care systems in the screening, outbreak prevention, and outbreak control process.

“We are awaiting verified data from COVID-19 positive tested people. This has to be done in a clinical trial to protect Data privacy,” the team behind the initiative said in a statement.

“Considering that we want to CLEAN a drum recording (highly explosive sounds), we removed low frequencies below 40 Hz and high frequencies above 15 kHz - 18 kHz because of microphone limitations. We also used a gate to remove unwanted noise between the coughs and make sure that you do not remove the “silent coughs” or “heavy breathing” because this might probably be important features for the model. Finally normalizing the sound, so that we do not have different loudness/ amplitudes among the files.”

The team hopes to classify cough sounds into two main categories; Covid-19 cough (dry cough) and Non-Covid-19 cough based on different cough patterns.

DetectNow are a non-profit, work for the social good, and are humanitarian and plan to stay that way. They hope their approach to cough analysis will provide a foundation towards further clinical research with AI on pulmonary diseases.

https://tribune.com.pk/story/2267058/local-startup-is-using-ai-to-detect-covid-19
 
Covid antibodies 'fall rapidly after infection'

Levels of protective antibodies in people wane "quite rapidly" after coronavirus infection, say researchers.

Antibodies are a key part of our immune defences and stop the virus from getting inside the body's cells.

The Imperial College London team found the number of people testing positive for antibodies has fallen by 26% between June and September.

They say immunity appears to be fading and there is a risk of catching the virus multiple times.

The news comes as figures from the Office for National Statistics show that the number of Covid-19 deaths in the UK rose by 60% in the week of 16 October.

The ONS figures suggest there have now been more than 60,000 deaths involving Covid-19 in the UK.

More than 350,000 people in England have taken an antibody test as part of the REACT-2 study so far.

In the first round of testing, at the end of June and the beginning of July, about 60 in 1,000 people had detectable antibodies.

But in the latest set of tests, in September, only 44 per 1,000 people were positive.

It suggests the number of people with antibodies fell by more than a quarter between summer and autumn.

"Immunity is waning quite rapidly, we're only three months after our first [round of tests] and we're already showing a 26% decline in antibodies," said Prof Helen Ward, one of the researchers.

The fall was greater in those over 65, compared with younger age groups, and in those without symptoms compared with those with full-blown Covid-19.

The number of healthcare workers with antibodies remained relatively high, which the researchers suggest may be due to regular exposure to the virus.

Read more: https://www.bbc.com/news/health-54696873
 
Covid vaccine: First 'milestone' vaccine offers 90% protection

The first effective coronavirus vaccine can prevent more than 90% of people from getting Covid-19, a preliminary analysis shows.

The developers - Pfizer and BioNTech - described it as a "great day for science and humanity".

Their vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised.

The companies plan to apply for emergency approval to use the vaccine by the end of the month.

A vaccine - alongside better treatments - is seen as the best way of getting out of the restrictions that have been imposed on all our lives.

There are around a dozen in the final stages of testing - known as a phase 3 trial - but this is the first to show any results.

It uses a completely experimental approach - that involves injecting part of the virus's genetic code - in order to train the immune system.

Previous trials have shown the vaccine trains the body to make both antibodies - and another part of the immune system called T-cells to fight the coronavirus.

Two doses, three weeks apart, are needed. The trials - in US, Germany, Brazil, Argentina, South Africa and Turkey - show 90% protection is achieved seven days after the second dose.

Pfizer believes it will be able to supply 50 million doses by the end of this year, and around 1.3 billion by the end of 2021.

However there are logistical challenges, as the vaccine has to be kept in ultra-cold storage at below minus 80C.

There are also questions about how long immunity lasts and the companies have not presented a breakdown of the vaccine's effectiveness in different age groups.

Dr Albert Bourla, the chairman of Pfizer, said: "We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis."

Prof Ugur Sahin, one of the founders of BioNTech, described the results as a "milestone".

The data presented is not the final analysis. It is based on the first 94 volunteers to develop Covid - the precise effectiveness of the vaccine may change when the full results are analysed.

The companies say they will have enough safety data by the third week of November to take their vaccine to regulators.

Until then it is not possible for countries to begin their vaccination campaigns. The UK has already put in an order for 40 million doses, enough for 20 million people.

"This news made me smile from ear to ear," Prof Peter Horby, from the University of Oxford.

"It is a relief... there is a long long way to go before vaccines will start to make a real difference, but this feels to me like a watershed moment."

https://www.bbc.co.uk/news/health-54873105
 
A woman who had #COVID19 when she was pregnant has given birth to a baby who has antibodies against the virus, according to a report
 
Babies born to Covid-19 mothers have antibodies: study

All five babies born to women with Covid-19 infection during a study in Singapore have had antibodies against the virus, although the researchers said it is not yet clear what level of protection this may offer.

The findings from a study of 16 women released on Friday also found that most were mildy infected, while more severe reactions occurred in older women with a high body mass index - a trend that is mirrored in the general population.

Of the five who had delivered their babies by the time the study was published, all had antibodies, according to the Singapore Obstetrics and Gynaecology Research Network.

The number of antibodies in the babies varied, and was higher among those whose mothers’ had been infected nearer to the time of delivery, the researchers said. Further monitoring is required to see whether the antibodies will decline as the babies get older, they added.

https://tribune.com.pk/live-blog/29
 
People who catch coronavirus for a second time likely to have milder symptoms, survey suggests

People who catch coronavirus for a second time have a lower viral load compared to the first infection, indicating they will have milder symptoms, a survey suggests.

Of 19,470 people surveyed who had previously been infected with coronavirus, 195 reinfections were identified, according to the Office for National Statistics (ONS) which compiled the survey.

Some 48 of those cases had a strong positive COVID-19 test, indicating a high viral load.

"This suggests that the number of reinfections is low overall, and reinfections with a high viral load (which are more likely to cause illness) are even lower," the report said.

The analysis found 99% of strong positive cases recorded in July were compatible with the Delta variant - first identified in India - compared to 92% in June and 46% in May.

It said people testing positive for COVID-19 with a strong positive test, indicating a higher viral load, were more likely to report "classic" symptoms such as a cough, fatigue or headache, rather than just loss of smell or gastrointestinal problems such as abdominal pain, diarrhoea, and nausea or vomiting.

The survey also suggested that one in four young adults who test positive for COVID are no longer following the rules for self-isolating.

Some 75% of respondents aged between 18 and 34 said they fully adhered to the isolation requirements for the entire 10-day period after testing positive for coronavirus.

This was "statistically significantly" lower than the percentage of 35 to 54-year-olds who said they followed the rules (86%), the ONS said.

The figures were based on responses collected from adults in England between 5 and 10 July.

They suggest most people are still following the requirement to self-isolate, although levels have dropped in the last two months.

Some 88% of 18 to 34-year-olds said they were adhering to self-isolation rules when surveyed between 10 and 15 May, compared with 75% in the latest survey.

Adherence among all adults has fallen from 86% in May to 79% in July.

The proportion of people saying self-isolation has affected their wellbeing has risen, however.

Around four in 10 (42%) of those who tested positive reported that isolating had had a negative effect on their mental health, up from 37% in May.

And 31% reported having lost income due to self-isolation, up from 27%.

"Full adherence to self-isolation requirements after testing positive for COVID-19 remains high, though we have seen a drop from May to July," said Tim Gibbs, head of the ONS public service analysis team.

"Self-isolation can have a negative impact on wellbeing and finances - nearly one third of people reported they lost income as a result of adherence and four in 10 said self-isolation had a negative impact on their wellbeing and mental health.

"With restrictions having relaxed further, it is important we continue to monitor the behaviour of those required to self-isolate."

The figures should be treated with care, the ONS added, as the survey was based on a relatively small sample of respondents who chose to report their own behaviour.

https://news.sky.com/story/covid-19...-survey-suggests-12367087?dcmp=snt-sf-twitter
 
Nasal Covid-19 vaccine by Bharat Biotech gets regulator’s nod for Phase 2 and 3 clinical trials

New Delhi: Bharat Biotech’s nasal Covid-19 vaccine, the first of its kind, has received the drug regulator’s nod for conducting Phase 2 and 3 clinical trials, the Department of Biotechnology informed on Friday.

The Phase 1 clinical trial was completed in the age groups ranging from 18-60 years.

“Bharat Biotech’s intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials,” the DBT said in its notification.

This is the first of its kind jab to undergo human trials in India.

The ‘BBV154’ is an intra-nasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine, and Bharat Biotech has in-licensed technology from Washington University in St Louis, US.

The company has reported that the doses of the vaccine administered to healthy volunteers in the Phase I trials have been well tolerated, and no serious adverse events were seen.

Previously, the vaccine was found to be safe, immunogenic, and well-tolerated in the pre-clinical toxicity studies. The shot was able to elicit high level of neutralising antibodies in animal studies.

The regulatory approval has been received for conducting ‘Phase 2 randomised, multi-centric, clinical trial of heterologous prime-boost combination of SARS-CoV-2 vaccines to evaluate the immunogenicity and safety of BBV152 (Covaxin) with BBV154 (Adenoviral Intranasal Covid-19 vaccine) in healthy volunteers’.

“The department, through mission Covid Suraksha, is committed to the development of safe and efficacious Covid-19 vaccines. Bharat Biotech's BBV154 Covid vaccine is the first intranasal vaccine being developed in the country entering into late-stage clinical trials,” Dr Renu Swarup, Secretary of Biotechnology and BIRAC Chairperson, said.

https://www.timesnownews.com/india/article/nasal-covid-19-vaccine-by-bharat-biotech-gets-regulators-nod-for-phase-2-3-clinical-trials/798828
 
India's drug regulator has approved the world's first DNA vaccine against Covid-19 for emergency use.

The three-dose ZyCoV-D vaccine prevented symptomatic disease in 66% of those vaccinated, according to an interim study quoted by the vaccine maker Cadila Healthcare.

The firm plans to make up to 120 million doses of India's second home-grown vaccine every year.

Previous DNA vaccines have worked well in animals but not humans.

India has so far given more than 570 million doses of three previously approved vaccines - Covishield, Covaxin and Sputnik V.

About 13% of adults have been fully vaccinated and 47% have received at least one shot since the beginning of the drive in January.

Cadila Healthcare said it had conducted the largest clinical trial for the vaccine in India so far, involving 28,000 volunteers in more than 50 centres.

This is also the first time, the firm claimed, a Covid-19 vaccine had been tested in young people in India - 1,000 people belonging to the 12-18 age group. The jab was found to be "safe and very well tolerated" in this age group.

The key third phase of clinical trials was conducted at the peak of the deadly second wave of the virus. The vaccine maker believes this reaffirmed the jab's "efficacy against the mutant strains", especially the highly infectious Delta variant.

"I am quite excited about the vaccine because it offers a lot of good potential. If this jab works, the future of vaccination becomes logistically simpler," said Prof Shahid Jameel, a well-known virologist.

How does this vaccine work?
DNA and RNA are building blocks of life. They are molecules that carry that genetic information which are passed on from parents to children.

Like other vaccines, a DNA vaccine, once administered, teaches the body's immune system to fight the real virus.

ZyCoV-D uses plasmids or small rings of DNA, that contain genetic information, to deliver the jab between two layers of the skin.

The plasmids carry information to the cells to make the "spike protein", which the virus uses to latch on and enter human cells.

Most Covid-19 vaccines work by giving the body instructions to make a fragment of the spike protein so it can trigger a person's immune system to produce antibodies and teach itself to fight off the virus.

What makes this vaccine different?
This is the world's first human DNA vaccine against Covid-19.

There are a number of DNA vaccines approved in the US, for example, for use in animals, including a vaccine for a disease in horses and a skin cancer vaccine for dogs.

Vaccines
However, more than 160 different DNA vaccines are being tested in human clinical trials in the US. Most are devoted to treating existing cancers, and a third of the vaccines were for treating HIV.

ZyCov-D is also India's first needle-free Covid-19 jab.

It is administered with a disposable needle-free injector, which uses a narrow stream of the fluid to penetrate the skin and deliver the jab to the proper tissue.

"To have a DNA vaccine which works against an infection is a big deal. If it gives good protection this is something India will be proud of," said Dr Gagandeep Kang, a virologist and the first Indian woman to be elected Fellow of the Royal Society of London.

What are the advantages of a DNA vaccine?
Scientists say DNA vaccines are relatively cheap, safe and stable.

They can also be stored at higher temperatures - 2 to 8C.

Cadila Healthcare claims that their vaccine had shown "good stability" at 25C for at least three months - this would help the vaccine to be transported and stored easily.

What are the drawbacks of a DNA vaccine?
DNA vaccines developed for infectious diseases in humans have failed in the past.

"The problem is they work well in animals. But they don't end up offering the same level of immune response protection in humans," said Dr Kang.

The challenge, according to Dr Kang, was how to push the plasmid DNA into the human cell so that it gives a durable immune response.

Dr Jeremy Kamil, a virologist at Louisiana State University Health Sciences Center in Shreveport, echoed a similar sentiment.

"Plasmid DNA vaccines have been tried in the past. But we know it's very difficult to get plasmid DNA into the nucleus of human cells, especially in adults," Dr Kamil told me.

mRNA vaccines - which use messenger RNA, a molecule, to make the proteins - like Pfizer or Moderna do not need to reach the nucleus of the cell to be effective and offer higher efficacy and are likely to produce longer lasting immunity.

The other potential drawback is that ZyCoV-D requires three doses, instead of two for the other two candidates being used in India. The vaccine maker says it is evaluating at a two-dose jab.

"I would be delighted that a vaccine company overcame the immense challenges to make it work. But it's imperative that the efficacy data be vetted independently," said Dr Kamil.

BBC
 
Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment


An investigational antiviral pill reduced the chances that patients newly diagnosed with Covid-19 would be hospitalized by about 50%, a finding that could give doctors a desperately needed new way to treat the sick, the drug maker Merck announced Friday.

A five-day course of molnupiravir, developed by Merck and Ridgeback Biotherapeutics, reduced both hospitalization and death compared to a placebo. In the placebo group, 53 patients, or 14.1%, were hospitalized or died. For those who received the drug, 28, or 7.3%, were hospitalized or died.

A simple oral medication to help treat Covid-19 has been an elusive goal since the start of the pandemic. Other drugs, including Gilead’s remdesivir, have also been shown to reduce hospitalizations if given early in the course of disease, but must be given intravenously.

“If this pans out, it will change the landscape,” said Andy Pavia, chief of the Division of Pediatric Infectious Diseases at University of Utah. “There’s still a lot we need to know. What does the side effect profile look like? Do we know how to dose it in populations that are different such as children and the obese? But as a top-line result, this is definitely exciting.”

Related: Scientists work toward an elusive dream: a simple pill to treat Covid-19
If approved, molnupiravir could have a dramatic impact on efforts to fight the pandemic. Merck and Ridgeback said they would seek an emergency use authorization from the Food and Drug Administration “as soon as possible” and would submit it to regulatory agencies worldwide.

The data from the study were made public in a press release and have not yet been peer-reviewed. But even top-line figures were encouraging. In the first 29 days of the study, there were no deaths reported in the group treated with molnupiravir and eight deaths reported among patients who received placebo.

Patients in the study had mild-to-moderate Covid-19, were within five days of symptom onset when dosed, and had at least one risk factor associated with poor disease outcomes.

The study was stopped early on the recommendation of an independent data monitoring committee and in consultation with the FDA, Merck said. Such committees are charged with making sure studies are in the best interest of patients, and recommend they be stopped if it is clear a drug is effective.

Only limited information on side effects was made public in the press release, but the companies said rates were similar between the placebo group and the treated group. An adverse event, or bad outcome, occurred in 35% of those who received molnupiravir and 40% of those who received placebo. Only 1.3% of molnupiravir-treated subjects discontinued the drug because of an adverse event, compared to 3.4% who discontinued placebo.

“When people talk about endemic Covid and the future of Covid, they don’t spend as much time talking about the value of intervening early to reduce severity of disease and that’s a very valuable tool,” said Natalie Dean, an assistant professor of biostatistics at Emory University who studies infectious disease. “The more accessible that can be, the more effective it can be.”

In an interview, Dean Li, Merck’s head of research and development, said that no particular side effect stood out as being more common with the drug, but more complete data will be available at a later date.

NEWSLETTERS
Sign up for The Readout
Your daily guide to what’s happening in biotech.

Enter your email
Privacy Policy
Molnupiravir works in a manner different from other antiviral drugs, creating multiple errors in the virus’s RNA and impairing its ability to replicate. Because there is not much experience with this mechanism, Pavia said, safety data will need to be scrutinized. He also said he doubted the drug will be used in pregnant people. None were included in the study.

DNA sequencing data on which variant of the SARS-CoV-2 caused Covid-19 was available in 40% of the 81 cases. The drug appeared effective against so-called variants of concern, including the Gamma, Delta, and Mu variants of the virus.

“As you are well aware, it is likely that we’re going to see continued evolution of those variants,” said Li. “Our prediction from our in vitro studies and now with this data is that molnupiravir is named after the right — you know, it’s named after Thor’s hammer [Mjollnir], this is a hammer against SARS-CoV-2 regardless of the variant.”

The study had enrolled 90% of the 1,500 volunteers it planned to include, but the decision to stop it was based on data from 762 patients. A breakdown on the background, ethnicity, and gender of the participants was not immediately available, but the trial was conducted in countries across the world, including Argentina, Italy, Japan, the United Kingdom, and the United States.

Li said the data monitoring committee met on Tuesday. He said he was in his kitchen when he received a text message from Roy Baynes, Merck’s chief medical officer. He said the results immediately impressed him.

“You think of all the people that could benefit from it and all the people that are in your life that you wish could have benefited from it,” Li said.

https://www.statnews.com/2021/10/01/mercks-antiviral-pill-reduces-hospitalization-of-covid-patients-a-possible-game-changer-for-treatment/
 
https://www.bbc.com/news/health-58801462

Scientists believe they can explain why some people who catch Covid develop chilblain-like lesions on their toes and even fingers.

Covid toe appears to be a side effect of the body switching into attack mode to fight off the virus.

The researchers say they have pinpointed the parts of the immune system that appear to be involved.

The findings, in the British Journal of Dermatology, may help with treatments to ease the symptoms.

What is Covid toe?

It can happen at any age, but affects children and teenagers more commonly.

For some it is painless, but the rash can be extremely sore and itchy, with tender blisters and swelling.

Sofia, who is 13 and from Scotland, was barely able to walk or wear shoes when she developed Covid toe earlier this year.

Over the summer, she told BBC Scotland's The Nine how she relied on a wheelchair for longer walks.

The affected skin - usually the toes, but sometimes the fingers - can look red or purple. Some people develop painful raised bumps or areas of rough skin. There can also be pus.

Some have it for months, others for weeks.

Often, they will have none of the classic Covid symptoms, such as the persistent cough, fever and loss or change in smell or taste.

Why does it happen?

These latest study findings, based on blood and skin tests, suggest two parts of the immune system may be at play.

Both involve mechanisms the body uses to fight coronavirus.

One is an antiviral protein called type 1 interferon, and the other is a type of antibody that mistakenly attacks the person's own cells and tissues, not just the invading virus.

Cells lining small blood vessels supplying the affected areas are also involved, say the investigators from the University of Paris, France.

The researchers studied 50 people with suspected Covid toe in the spring of 2020, and 13 others with similar chilblains lesions that were not linked to Covid infections, because they occurred long before the pandemic began.

They hope the finds will help patients and doctors better understand the condition.

UK podiatrist Dr Ivan Bristow said, for most - like the regular chilblains typically seen during cold spells and in people who have problems with circulation - the lesions usually go away on their own.

But some may need treatment with creams and other drugs.

"The confirmation of the cause will help to develop new treatments to manage it more effectively," he said.

Dr Veronique Bataille, a consultant dermatologist and spokeswoman for the British Skin Foundation, said Covid toe was seen very frequently during the early phase of the pandemic, but has been less common in the current Delta variant wave.

That might be down to more people being vaccinated or having some protection against Covid from past infections.

"Presentations after vaccination are much rarer," she said.

Covid-related skin problems can appear quite a while after the acute infection and in people who have no other symptoms, so the link with the virus is sometimes not made, she said.
 
Lateral flow tests (LFTs) are very good at detecting people most likely to spread Covid-19 and positive results should be trusted, say University College London researchers.

When LFTs were introduced, they were criticised for being less accurate than PCR tests, which are analysed in a lab.

But the study found rapid tests were "a very useful public health tool" for stopping the spread of the virus.

One third of people with Covid can spread it while showing no symptoms.

Based on the UCL research, Prof Irene Petersen, lead study author, said people who get a positive LFT result "should trust them and stay at home".

But government guidance says people must get a follow-up PCR test after a positive LFT to confirm they have Covid - and they can end their self-isolation when they get a negative result in a PCR test.

There have been recent reports of this happening in south-west England, leaving people unsure whether to isolate or not.

The UK's Health Security Agency said it was looking into the cause, but there was no evidence of any technical issues with test kits.

Prof Petersen said: "When [Covid is] more common, there is no need to confirm it with a PCR - it's more likely it is a positive," she said.

Rapid results

When the researchers used a new formula for calculating the rapid test's accuracy, they found LFTs were more than 80% effective at detecting any level of Covid-19 infection and likely to be more than 90% effective at detecting who is most infectious when they use the test.

This is much higher than previously thought, they say.

Prof Michael Mina, from Harvard School of Public Health, also part of the research team, said the LFTs could "catch nearly everyone who is currently a serious risk to public health" when viral loads are at their peak.

"It is most likely that if someone's LFT is negative but their PCR is positive, then this is because they are not at peak transmissible stage," he said.

The rapid tests are widely used in schools, workplaces and for allowing entry to large events to test those with no symptoms.

'Apples and oranges'
Since they were introduced in secondary schools in England in March, NHS Test and Trace figures show 103,409 LFT tests have come back positive, 79,000 were matched with a confirmatory PCR and 69,500 of those were confirmed positive (and 7,647 came back negative).

There was much criticism of the rapid tests when they were first trialled in Liverpool last year because they were directly compared to PCR tests, which were often described as the gold standard.

"This is like comparing apples and oranges," Prof Petersen said.

Lateral flow tests and PCR (polymerase chain reaction) tests do different things:

LFTs pick up the most infectious people by detecting material from the surface proteins of the virus
PCRs detect genetic material of the virus which can be present in the body for several weeks after somebody is actually capable of passing it on

'Confused'
The UCL peer-reviewed study concludes that criticism of LFTs for low sensitivity "have reached the wrong conclusions", "confused policy-making" and "damaged public trust in LFTs".

Health professionals and the public should be aware of what the tests do, said the researchers, writing in Clinical Epidemiology.

And they acknowledge that errors in the way people take the tests or in the way they are processed in the lab could affect results - and these factors were not taken into account in their study.

The current government guidance says that if you receive a negative follow-up PCR test result, and this PCR test was taken within two days of the positive LFT, you will be told by NHS Test and Trace that you can stop self-isolating.

However, it states that you must continue to self-isolate if the PCR result is positive, you choose not to take a follow-up PCR or the test was taken more than two days after the positive LFT.

Dr Sophia Makki, incident director for Covid-19 at the UK Health Security Agency, said: "Around one in three people who have Covid-19 never show any symptoms.

"Using LFDs (lateral flow devices) help to find asymptomatic cases who have a high viral load and are most likely to pass on the virus to others."

BBC
 
Officials are keeping a close watch on a new descendant of the Delta variant of Covid that is causing a growing number of infections.

Delta is the UK's dominant variant, but latest official data suggests 6% of Covid cases that have been genetically sequenced are of a new type.

AY.4.2, which some are calling "Delta Plus", contains mutations that might give the virus survival advantages.

Tests are under way to understand how much of a threat it may pose.

Experts say it is unlikely to take off in a big way or escape current vaccines.

It is not yet considered a variant of concern, or a variant under investigation - the categories assigned to variants and the level of risk associated with them.

What is AY.4.2?

There are thousands of different types - or variants - of Covid circulating across the world. Viruses mutate all the time, so it is not surprising to see new versions emerge.

Original Delta was classified as a variant of concern in the UK in May 2021 after overtaking the Alpha variant to become the dominant type of Covid in circulation.

But in July 2021 experts identified AY.4.2.

This offshoot or sublineage of Delta has been increasing slowly since then. It includes some new mutations affecting the spike protein, which the virus uses to penetrate our cells.

So far, there is no indication that it is considerably more transmissible as a result of these changes, but it is something experts are studying.

The mutations - Y145H and A222V - have been found in various other coronavirus lineages since the beginning of the pandemic.

BBC
 
Jabs do not reduce risk of passing Covid within household, study suggests

People who are fully vaccinated against Covid yet catch the virus are just as infectious to others in their household as infected unvaccinated people, research suggests.

Households are a key setting for the transmission of Covid infections (pdf), with frequent prolonged daily contact with an infected person linked to an increased risk of catching the virus.

However, questions have remained – including the true proportion of household contacts who become infected from an initial case, the duration of their infection, and the impact of vaccination on the risk of transmitting the virus and the chance of catching it.

Now a study has revealed that while vaccination against Covid is crucial to preventing severe disease and death, even fully jabbed individuals catch the virus – and pass it on.

Writing in the Lancet, researchers from a number of institutions including Imperial College London and the UK Health Security Agency (HSA) report how they analysed data from 204 household contacts of 138 people infected with the Delta variant.

Of these contacts, who were recruited within five days of their household member showing symptoms and were tested daily for 14 days, 53 went on to become infected, 31 of whom were fully vaccinated and 15 were unvaccinated.

The results suggest even those who are fully vaccinated have a sizeable risk of becoming infected, with analysis revealing a fully vaccinated contact has a 25% chance of catching the virus from an infected household member while an unvaccinated contact has a 38% chance of becoming infected.

However, the figures do not shed light on the severity of illness, while the team cautions these figures fall within a range of possible values, meaning the exact size of the difference is unclear.

The analysis further suggests that whether an infected individual is themselves fully vaccinated or unvaccinated makes little or no difference to how infectious they are to their household contacts.

The team add that the peak level of virus in infected individuals was the same regardless of whether they were jabbed or not, although these levels dropped off more quickly in the vaccinated people, suggesting they cleared the infection sooner.

“This likely explains why [fully vaccinated] breakthrough cases are as infectious to their contacts as [unvaccinated] cases” said Prof Ajit Lalvani, chair of infectious diseases at Imperial College London and an author of the study.

The team also looked more closely at those who were fully vaccinated.

“What we found, surprisingly, was that already by three months after receipt of the second vaccine dose, the risk of acquiring infection was higher compared to being more recently vaccinated,” said Lalvani.

“This suggests that vaccine-induced protection is already waning by about three months post-secondary,” he added.

Lalvani stressed that vaccination, including boosters, was important, noting that unvaccinated people cannot rely on the immunity of those who are fully jabbed for protection.

Should fully vaccinated individuals become infected, he added, they remain protected against severe disease and death, and tend to have only a mild infection.

However, when asked if the data suggested booster doses should be offered sooner than six months after a second jab, Lalvani said the emphasis should be on encouraging those already eligible to take the extra dose.

Prof Rowland Kao, an epidemiologist at the University of Edinburgh, who was not involved in the work, said the estimates of high rates of transmission among household contacts underscored the need to vaccinate teenagers and give boosters to vulnerable people.

“The vaccinations of younger persons to slow down transmission in the community, and the boosters to directly protect against severe infection and hospitalisation,” he said.

Kao suggested the findings also added weight to calls for the introduction of further measures in the UK to tackle the spread of Covid, adding the move could also mitigate the risks posed by other respiratory infections including flu.

“The result that vaccinated individuals who become infected appear to pose a similar infection risk to others also emphasizes the need for continued or improved non-pharmaceutical interventions to further slow down transmission rates and ease hospital burdens over the winter,” he said.

https://www.theguardian.com/world/2...ely-unjabbed-infect-cohabiters-study-suggests

discuss
 
https://www.reuters.com/business/healthcare-pharmaceuticals/britain-approves-mercks-oral-covid-19-pill-2021-11-04/

Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) recommended the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.

It will be administered as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, the regulator said, citing clinical data.

The green light is the first for an oral antiviral treatment for COVID-19 and the first for a COVID-19 drug that will be administered widely in the community. U.S. advisers will meet this month to vote on whether molnupiravir should be authorized.

Treatments to tackle the pandemic, which has killed more than 5.2 million people worldwide, have so far focused mainly on vaccines. Other options, including Gilead's infused antiviral remdesivir and generic steroid dexamethasone, are generally only given after a patient has been hospitalised.

Merck's Molnupiravir has been closely watched since data last month showed it could halve the chances of dying or being hospitalised for those most at risk of developing severe COVID-19 when given early in the illness.

Molnupiravir, which will be branded as Lagevrio in Britain, is designed to introduce errors into the genetic code of the coronavirus that causes COVID-19 and is taken twice a day for five days.

Professor Stephen Powis, national medical director for the National Health Service (NHS) in England, said the drug would be administered to patients at higher risk of complications as Britain heads into one of the most challenging winters ever.

A wider rollout will follow if it is clinically and cost effective in reducing hospitalisations and death, he added.

"We are now working across government and the NHS to urgently get this treatment to patients initially through a national study so we can collect more data on how antivirals work in a mostly vaccinated population," UK vaccines minister Maggie Throup told parliament.

The speedy approval in Britain, which was also the first Western country to approve a COVID-19 vaccine, comes as it struggles to tame soaring infections.

Britain has about 40,000 daily cases of COVID-19, according to the latest seven-day average. That is second only to the roughly 74,000 a day in the United States, which has five times more people, and has fuelled criticism of the government's decision to abandon most pandemic-related restrictions.

Data released on Wednesday night showed COVID-19 prevalence in England hit its highest level on record last month, led by a high numbers of cases in children and a surge in the south-west of the country.

Pressure is growing on the government to implement its "Plan B" aimed at protecting the NHS from unsustainable demands, involving mask mandates, vaccine passes and work-from-home orders.

Many other big economies, including Germany, France and Israel, have either retained some basic COVID-19 measures like mask mandates or reintroduced them in response to rising cases.

The UK government has said its focus remains on administering vaccine boosters and inoculating 12 to 15-year-olds.

"With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data (on molnupiravir)," MHRA chief June Raine said in a statement.

Last month, Britain agreed a deal with Merck to secure 480,000 courses of molnupiravir.

Professor Penny Ward, an independent pharmaceutical physician, welcomed the approval, but said the NHS needed to outline its plans for rollout and cautioned that supplies were likely to be tight given the strong global demand.

"Comments made by Mr Javid today suggest that it may be made available via a clinical trial, presumably to investigate its effectiveness in vaccinated patients with breakthrough infections, as the original study incorporated unvaccinated adults," she said.

If given to everyone becoming unwell, the nearly half a million courses would not last very long given the more than 40,000 current daily case rate, she said.

In a separate statement, Merck said it expected to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.

The U.S. based drugmaker's shares were up 2.1% at $90.54 before the market open.

Pfizer and Roche are also racing to develop easy-to-administer antiviral pills for COVID-19. Pfizer last month began a large study of its oral antiviral drug for the prevention of COVID-19 in people exposed to the coronavirus.

Merck's molnupiravir is also being studied in a late-stage trial for preventing infection.

Viral sequencing done so far has shown molnupiravir is effective against all variants of the coronavirus, Merck has said, including the more-infectious Delta, which is responsible for the worldwide surge in hospitalisations and deaths recently.

While it is not yet clear when Merck will deliver doses to Britain, the company has said it is committed to providing timely access to its drug globally with plans for tiered pricing aligned with a country's ability to pay.

Merck is also in talks with generic drugmakers about expanding manufacturing licences to build supply of the treatment.

Antibody cocktails like those from Regeneron and Eli Lilly have also been approved for non-hospitalised COVID-19 patients, but have to be given intravenously.
 
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-antiviral-pill-cuts-risk-severe-covid-19-by-89-2021-11-05/

A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.

The results appear to surpass those seen with Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.

Full trial data is not yet available from either company.

Pfizer shares surged 11% to $48.55, while those of Merck fell 8.5% to $82.80. Shares of vaccine makers also took a hit, with Moderna Inc, Pfizer's German partner BioNTech SE and Novavax all down nearly 7%.

Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.

That filing is expected to be submitted before Thanksgiving, Pfizer Chief Executive Albert Bourla said in an interview with CNBC.

The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.

The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.

It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.

Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths. Bourla said that works out to being 85% effective.

The data compared favorably to Merck's oral antiviral in a similar patient population, Cantor Fitzgerald analyst Louise Chen said in a note.

With the virus still circulating widely and current therapeutic options requiring access to a healthcare facility, antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed, Chen said.

Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.

"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective," Annaliesa Anderson, head of the Pfizer program, told Reuters.

The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients. Ritonavir's possible side effects include nausea and diarrhea.

"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations," Bourla said in a statement.

Pfizer said it was currently expecting to produce more than 180,000 packs by the end of 2021 and at least 50 million packs by the end of 2022, of which 21 million would be produced in the first half.

Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.

Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.

Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.

Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.

Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.
 
T-cells from common colds can provide protection against COVID-19 - study

LONDON, Jan 10 (Reuters) - High levels of T-cells from common cold coronaviruses can provide protection against COVID-19, an Imperial College London study published on Monday has found, which could inform approaches for second-generation vaccines.

Immunity against COVID-19 is a complex picture, and while there is evidence of waning antibody levels six months after vaccination, T-cells are also believed to play a vital role in providing protection.

The study, which began in September 2020, looked at levels of cross-reactive T-cells generated by previous common colds in 52 household contacts of positive COVID-19 cases shortly after exposure, to see if they went on to develop infection.

It found that the 26 who did not develop infection had significantly higher levels of those T-cells than people who did get infected. Imperial did not say how long protection from the T-cells would last.

"We found that high levels of pre-existing T cells, created by the body when infected with other human coronaviruses like the common cold, can protect against COVID-19 infection," study author Dr Rhia Kundu said.

The authors of the study, published in Nature Communications, said that the internal proteins of the SARS-CoV-2 virus which are targeted by the T-cells could offer an alternative target for vaccine makers.

Current COVID-19 vaccines target the spike protein, which mutates regularly, creating variants such as Omicron which lessen the efficacy of vaccines against symptomatic infection.

"In contrast, the internal proteins targeted by the protective T-cells we identified mutate much less," Professor Ajit Lalvani, co-author of the study, said.

"Consequently, they are highly conserved between the various SARS-CoV-2 variants, including Omicron. New vaccines that include these conserved, internal proteins would therefore induce broadly protective T cell responses that should protect against current and future SARS-CoV-2 variants."

https://www.reuters.com/business/he...protection-against-covid-19-study-2022-01-10/
 
<b>Scans reveal how Covid may change the brain</b>

Catching Covid may cause changes to the brain, a study suggests.

Scientists found significant differences in MRI (magnetic resonance imaging) scans before and after infection.

Even after a mild infection, the overall size of the brain had shrunk slightly, with less grey matter in the parts related to smell and memory.

The researchers do not know whether the changes are permanent but stressed the brain could heal.

The study is published in the journal <I>Nature</I>.

Lead author Prof Gwenaelle Douaud, from the Wellcome Centre for Integrative Neuroimaging, at the University of Oxford, said:

"We were looking at essentially mild infection, so to see that we could really see some differences in their brain and how much their brain had changed compared with those who had not been infected was quite a surprise."

The UK Biobank project has followed the health of 500,000 people for about 15 years and has a database of scans recorded before the pandemic so provided a unique opportunity to study the long-term health impacts of the virus.

The scientists rescanned:
— 401 participants 4.5 months, on average, after their infection, 96% of whom had had mild Covid
— 384 participants who had not had Covid

They found:
— The overall brain size in infected participants had shrunk between 0.2 and 2%
— There were losses in grey matter in the olfactory areas, linked to smell, and regions linked to memory
— Those who had recently recovered from Covid found it a bit harder to perform complex mental tasks
— But the researchers do not know whether the changes are reversible or truly matter for health and wellbeing.

"We need to bear in mind that the brain is really plastic - by that we mean it can heal itself - so there is a really good chance that, over time, the harmful effects of infection will ease," Prof Douaud said.

The most significant loss of grey matter was in the olfactory areas - but it is unclear whether the virus directly attacks this region or cells simply die off through lack of use after people with Covid lose their sense of smell.

It is also unclear whether all variants of the virus cause this damage.

The scans were performed when the original virus and alpha variant were prevalent and loss of smell and taste a primary symptom.

But the number of people infected with the more recent Omicron variant reporting this symptom has fallen dramatically.

https://www.bbc.co.uk/news/health-60591487
 
A city of 17.5 million people in China has gone into lockdown after a spike in coronavirus cases in neighbouring Hong Kong.

Everyone in Shenzhen will undergo three rounds of COVID-19 testing after 60 new cases were reported on Sunday.
 
What is the Deltacron variant of Covid and where has it been found?

What is Deltacron?
As the portmanteau suggests, Deltacron is a Covid variant that contains elements of Delta and Omicron – in other words, it contains genes from both variants, making it what is known as a recombinant virus.

“These recombinants arise when more than one variant infects and replicates in the same person, in the same cells,” says Prof Lawrence Young, a virologist at the University of Warwick. “Deltacron is a product of both the Delta and Omicron variants circulating in the same population.”

This week, Gisaid, a global community of scientists that shares virus information, posted that the first solid evidence for this variant had been shared by the Pasteur Institute in France.

Where has this variant been found?
Gisaid says the variant has been identified in several regions of France and appears to have been circulating since the start of the year. “Genomes with a similar profile have been also identified in Denmark and the Netherlands,” Gisaid says.

There have also been reports of Deltacron being detected in the US, and about 30 cases have been detected in the UK, according to the UK Health Security Agency (UKHSA). The i newspaper said the first cases of person-to-person transmission of Deltacron in the UK were expected to be confirmed this week.

Dr Etienne Simon-Loriere of the Institut Pasteur cautioned that there could be several different recombinant viruses formed from Delta and Omicron.

“The one we see in France and in Denmark/Netherlands look super similar and might be the same recombinant (with the same parental viruses) that have travelled,” he said. But, he added, the possible Delta-Omicron recombinants reported in countries including the UK and US appear to combine different pieces of their parental viruses, and therefore differ to the Deltacron seen in France.

“We might need to find a different name to indicate these recombinant, or start adding a number,” he said.

How worried should we be?
Experts have been quick to stress that recombinant variants are not uncommon, and that Deltacron is not the first and will not be the last to occur for Covid.

“This happens whenever we are in the switchover period from one dominant variant to another, and is usually a scientific curiosity but not much more than that,” says Dr Jeffrey Barrett, who formerly led the Covid-19 genomics initiative at the Wellcome Trust Sanger Institute.

With only a small number of cases of Deltacron so far identified, however, there is not yet enough data about the severity of the variant or how well vaccines protect against it.

Soumya Swaminathan, the chief scientist at the World Health Organization, tweeted on Tuesday: “We have known that recombinant events can occur, in humans or animals, with multiple circulating variants of #SarsCoV2. Need to wait for experiments to determine the properties of this virus. Importance of sequencing, analytics and rapid data sharing as we deal with this pandemic.”

Young agrees. “We need to keep an eye on the behaviour of this recombinant in terms of its transmissibility and its ability to escape vaccine-induced immune protection,” he says. “This also serves to reinforce the need to maintain genetic surveillance. As the virus continues to circulate, particularly in under-vaccinated populations and in people whose vaccine-induced immunity is decaying, we are very likely to see more variants including those generated through recombination.”

But that does not mean the variant is a reason to panic: according to the UKHSA, the variant is not exhibiting a growth rate of concern.

“It has been seen in the UK a small number of times, and so far seems to be very rare anywhere in the world, with only a few dozen sequences among the millions of Omicrons,” says Barrett. “So I don’t think it’s anything to be concerned about at present, though I’m sure it will continue to be monitored.”

Previous waves of Delta and Omicron, as well as vaccinations, mean there is likely to be at least some protection against this variant.

https://www.google.com/amp/s/amp.th...022/mar/11/what-is-deltacron-covid-variant-uk
 
People living in poverty are more likely to suffer with long COVID, a new study suggests.

According to the Institute for Fiscal Studies (IFS), people with coronavirus symptoms lasting more than four weeks are more likely to have been living in social housing or claiming benefits before they got ill.

Previous studies have shown that long COVID patients are more likely to be women, middle-aged and have an underlying health condition.

The IFS research, which uses data from the Office for National Statistics (ONS) UK Household Longitudinal Study and Understanding Society figures, indicates that one in 10 long COVID patients stop working while they still have symptoms.

This means that getting long COVID increases your chances of having to decrease working hours by six percentage points.

For those who do have to reduce their workload, this equates to an average of two-and-a-half fewer hours worked a week or £65 a month.

The IFS research also suggests that given 3% of the UK population had long COVID as of May this year, 110,000 workers are off sick from the condition at any one time.

SKY
 
Covid Was Man-Made Virus, Says Wuhan Lab Scientist In New Book

New Delhi:

In what appears to be an astonishing revelation, a US-based scientist, who worked at a controversial research lab in China's Wuhan, has said that COVID-19 was a "man-made virus" that leaked from the facility.

Covid was leaked from Wuhan Institute of Virology (WIV), a state-run and funded research facility, two years ago, the New York Post reported, quoting US-based researcher Andrew Huff's statement in the British newspaper The Sun.

In his latest book, "The Truth About Wuhan," epidemiologist Huff claims that the pandemic was caused by the US government's funding of coronaviruses in China. Excerpts of Huff's book have been out in the UK-based tabloid The Sun.

According to the New York Post report, Mr Huff is the former vice president of the EcoHealth Alliance, a non-profit organisation based in New York that studies infectious diseases.

Mr Huff claims in his book that China's gain-of-function experiments were conducted with inadequate security, resulting in a leak at the Wuhan lab, according to New York Post.

The Wuhan lab has been the centre of heated debates over the origins of COVID, with both Chinese government officials and lab workers denying that the virus originated there.

"Foreign laboratories did not have the adequate control measures in place for ensuring proper biosafety, biosecurity, and risk management, ultimately resulting in the lab leak at the Wuhan Institute of Virology," Andrew Huff, said in his book.

For more than a decade, the organisation has been studying several coronaviruses in bats with funding from the National Institutes of Health (NIH) and has forged close ties to the Wuhan lab.

The NIH is the primary agency of the United States government responsible for biomedical and public health research.

Mr Huff, who worked at EcoHealth Alliance from 2014 to 2016, stated that the non-profit assisted the Wuhan lab for many years in developing the "best existing methods to engineer bat coronaviruses to attack other species"

"China knew from day one that this was a genetically engineered agent," Huff wrote. "The US government is to blame for the transfer of dangerous biotechnology to the Chinese.

"I was terrified by what I saw," he told The Sun, as per New York Post. "We were just handing them bioweapon technology."

The Post also reports that according to a recent investigation published by ProPublica/Vanity Fair, the WIV is home to China's riskiest coronavirus research.

This research institute has been under immense pressure from the ruling Chinese Communist Party to produce scientific breakthroughs to raise its global status despite the lack of resources.

NDTV
 
Covid: FBI chief Christopher Wray says China lab leak 'most likely'

FBI Director Christopher Wray has said that the bureau believes Covid-19 "most likely" originated in a "Chinese government-controlled lab".

"The FBI has for quite some time now assessed that the origins of the pandemic are most likely a potential lab incident," he told Fox News.

It is the first public confirmation of the FBI's classified judgement of how the pandemic virus emerged.

China has denied a lab leak in Wuhan, calling the allegation defamatory.

Mr Wray's comments come a day after the US ambassador to China called for the country to "be more honest" about Covid's origins.

In his interview on Tuesday, Mr Wray said China "has been doing its best to try to thwart and obfuscate" efforts to identify the source of the global pandemic.

"And that's unfortunate for everybody," he said.

Some studies suggest the virus made the leap from animals to humans in Wuhan, China, possibly at the city's seafood and wildlife market.

...
https://www.bbc.com/news/world-us-canada-64806903
 
The origins of Covid-19 are being explored by a US congressional committee in a first hearing in Washington.

The panel, formed by a new Republican majority in the US House of Representatives, is aiming to establish how the coronavirus emerged.

Some US officials have concluded that Covid "most likely" came from an unintended lab leak in Wuhan, China.

But many scientists point out there is no evidence that it leaked from a lab.

And the White House has said there is no consensus across the US government on the virus's origins.

The committee of nine Republicans and seven Democrats has said it would aim to conduct its work above partisanship.

But at Wednesday's hearing, the committee's top Democrat Raul Ruiz argued against the inclusion of witness Nicholas Wade over a controversial book he authored.

Mr Ruiz said the former New York Times journalist's inclusion was dangerous and that he could not be relied on.

The congressman said the former leader of the Ku Klux Klan, Dr David Duke, had endorsed a 2014 book by Mr Wade, which argued races evolved differently.

Mr Wade denied it was a racist book and another key witness, Dr Robert Redfield, the former director of the US Centers for Disease Control and Prevention, defended Mr Wade as "an outstanding science writer".

Dr Redfield was an early proponent of the lab leak theory, and used his appearance on Wednesday to restate his opposition to so-called gain of function research, in which viruses are manipulated to become more infectious in lab environments.

He told the committee it was "not scientifically plausible" to him that the virus had natural origins.

"It was told to me that they wanted a single narrative, and that I obviously had a different point of view," he said.

Some studies suggest the virus made the leap from animals to humans in Wuhan, possibly at the city's seafood and wildlife market.

The market is near a world-leading virus laboratory, the Wuhan Institute of Virology, which conducted research into coronaviruses.

Dr Redfield told the committee he believed the US taxpayer had funded gain of function research at the Wuhan institute.

Last week, FBI Director Christopher Wray said the bureau considered a potential laboratory leak as the "most likely" origin of Covid.

A few days before that, the US Department of Energy said it had found the virus was most likely the result of a lab leak in Wuhan, but could only reach that conclusion with "low confidence".

In response to that, many scientists who have studied the virus said that there was no new scientific evidence pointing to a lab leak.

A natural origin is still the more likely theory, said Professor David Robertson, head of viral genomics and bioinformatics at the University of Glasgow.

BBC
 
The possibility the Covid virus leaked from a laboratory should not be ruled out, a former top Chinese government scientist has told BBC News.

As head of China's Centre for Disease Control (CDC), Prof George Gao played a key role in the pandemic response and efforts to trace its origins.

China's government dismisses any suggestion the disease may have originated in a Wuhan laboratory.

But Prof Gao is less forthright.

In an interview for the BBC Radio 4 podcast Fever: The Hunt for Covid's Origin, Prof Gao says: "You can always suspect anything. That's science. Don't rule out anything."

A world-leading virologist and immunologist, Prof Gao is now vice-president of the National Natural Science Foundation of China after retiring from the CDC last year.

In a possible sign that the Chinese government may have taken the lab leak theory more seriously than its official statements suggest, Prof Gao also tells the BBC some kind of formal investigation into the Wuhan Institute of Virology (WIV) was carried out.

"The government organised something," he says, but adds that it did not involve his own department, the China CDC.

We asked him to clarify whether that meant another branch of government carried out a formal search of the WIV - one of China's top national laboratories, known to have spent years studying coronaviruses.

"Yeah," he replies, "that lab was double-checked by the experts in the field."

It's the first such acknowledgement that some kind of official investigation took place, but while Prof Gao says he has not seen the result, he has "heard" that the lab was given a clean bill of health.

"I think their conclusion is that they are following all the protocols. They haven't found [any] wrongdoing."

BBC
 
No direct proof Covid-19 stemmed from Wuhan lab leak, US intelligence says
Four-page declassified report said while ‘extensive work’ had been conducted, no evidence of an incident at the Wuhan lab was found

US intelligence agencies found no direct evidence that the Covid-19 pandemic stemmed from an incident at China’s Wuhan Institute of Virology, a report declassified on Friday said.

The four-page report by the office of the director of national intelligence (ODNI) said the US intelligence community still could not rule out the possibility that the virus came from a laboratory, however, and had not been able to discover the origins of the pandemic.

“The Central Intelligence Agency and another agency remain unable to determine the precise origin of the Covid-19 pandemic, as both (natural and lab) hypotheses rely on significant assumptions or face challenges with conflicting reporting,” the ODNI report said.

The report said that while “extensive work” had been conducted on coronaviruses at the Wuhan institute (WIV), the agencies had not found evidence of a specific incident that could have caused the outbreak.

“We continue to have no indication that the WIV’s pre-pandemic research holdings included SARS-CoV-2 or a close progenitor, nor any direct evidence that a specific research-related incident occurred involving WIV personnel before the pandemic that could have caused the Covid pandemic,” the report said.

Intelligence officials have been pushed by lawmakers to release more material about the origins of Covid-19. But they have repeatedly argued China’s official obstruction of independent reviews has made it perhaps impossible to determine how the pandemic began.

The newest report is likely to anger Republicans who say the administration is wrongly withholding classified information and researchers who accuse the US of not being forthcoming.

...
https://www.theguardian.com/us-news...rigins-wuhan-lab-leak-us-intelligence-reports
 
Back
Top